Related Experiment Videos
Prostate-specific antigen and androgen deprivation therapy
1Department of Urology, Mayo Clinic, Rochester, MN 55905.
World Journal of Urology
|January 1, 1993
Summary
Prostate-specific antigen (PSA) is a key marker for prostate cancer detection and monitoring. While androgen deprivation therapy (ADT) can lower PSA levels by reducing gene expression, PSA remains valuable for predicting treatment response and progression.
Area of Science:
- Oncology
- Biochemistry
Background:
- Prostate-specific antigen (PSA) is a vital biomarker for prostate cancer, aiding in early detection and treatment monitoring.
- Androgen deprivation therapy (ADT) is a common treatment for prostate cancer, often leading to decreased serum PSA levels.
Purpose of the Study:
- To investigate the relationship between androgen deprivation therapy (ADT) and prostate-specific antigen (PSA) levels in prostate cancer patients.
- To clarify whether decreased PSA during ADT reflects therapeutic efficacy or hormonal regulation of PSA gene expression.
Main Methods:
- Review of existing literature on PSA, ADT, and androgen receptor signaling.
- Analysis of studies examining PSA dynamics in response to various ADT modalities.
Main Results:
- ADT, including orchiectomy and hormonal agents, typically reduces serum PSA concentrations.
- Evidence suggests that androgens directly regulate PSA gene expression via the androgen receptor.
- Lowered PSA during ADT may result from hormonal down-regulation, not solely from antitumor effects.
Conclusions:
- While ADT impacts PSA expression, PSA remains a crucial marker for prognosticating ADT response and predicting clinical progression in prostate cancer.
- Understanding the dual effect of ADT on PSA (direct gene regulation and therapeutic effect) is essential for accurate patient management.